
866-unit subdivision being proposed for the outskirts of Arthur
ARTHUR – A proposed housing development could bring almost 900 new residential lots to Arthur in the coming years.
Developer Tribute/Sorbara Arthur Holdings Inc. has applied for an official plan bylaw amendment to construct 866 housing units on 55.34 hectares at 665 Eliza St. and a vacant lot west of Eliza Street, a rural spot just northeast of the town proper.
The applicant is seeking an Official Plan amendment and zoning changes to permit the development to redesignate the subject lands from 'future development' to 'residential'.
Currently occupied by a farmstead and cropland with frontage on Eliza Street, the development is proposed to comprise 504 single detached residential units, 114 semi-detached residential lots, 249 street townhouse units, parks, a stormwater management pond, a well and a sanitary pumping station.
'The proposed development will transform agricultural and low-density residential land into a community with housing, parks, and essential infrastructure,' said the planning justification report.
According to the report, the development will not include affordable housing units and is instead proposing a range of housing types to ensure 'broader housing options for people in different life stages.'
A noise compatibility assessment found existing and future industrial uses to the south and northeast of the development may exceed the MECP noise limits, but is feasible with 'appropriate noise mitigation measures' like forced air ventilation, noise barriers of up to six metres, redesignating the area, and/or warning clauses in property agreements.
Proposed to have access to Eliza Street and Macaulay Street, which remains unopened, the report says the existing and future road connections and future internal road network will accommodate the daily anticipated traffic levels of 478 and 646 vehicle trips. A future signal installation at Eliza and Tucker may be considered.
Given Arthur's servicing constraints, the development will require a new sewage pumping station and an upgrade to the existing wastewater treatment plant, which the report proposes should be included in the township's final municipal strategy. A new well is proposed at the intersection of Macaulay and Wells Street.
While a buffer zone with parks is proposed between the residential units and nearby dust emission sources at Clark Brothers Contracting and Teeswater Concrete Ltd. to alleviate future air quality issues, the proposed development is considered adequately distanced from nearby industrial and agricultural cities to avoid negative impacts on air quality and unpleasant smells.
Since Farley Creek crosses the site, 2.62 hectares is proposed to be preserved as a protected natural environmental area.
With two elementary schools, a private school and no high school located near the site, local school boards have been asked to identify the existing school capacity.
The full report is available
here
.
Isabel Buckmaster is the Local Journalism Initiative reporter for GuelphToday. LJI is a federally-funded program.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Protect nine household devices with this $16 app
The following content is brought to you by Mashable partners. If you buy a product featured here, we may earn an affiliate commission or other compensation. TL;DR: Protect up to nine devices for life with AdGuard, now just $16 with code FAMPLAN through July 20. The internet is full of distractions and worse. Between invasive ads, data trackers, phishing scams, and inappropriate content, your digital life (and your family's) deserves better online protection. AdGuard can help be there when you're not thinking about protection, and for a limited time, you can get lifetime access to the AdGuard Family Plan for just $15.97 (MSRP $169.99) when you use code FAMPLAN by July 20. AdGuard is more than your average ad blocker. It's a cross-platform privacy tool that cleans up your online experience across browsers and apps. It blocks pop-ups, autoplay videos, trackers, and even malicious links—keeping your browsing faster, cleaner, and safer. The Family Plan covers up to nine devices, so everyone in your household, from kids to grandparents, can enjoy safer browsing on their phones, tablets, or computers. AdGuard's parental control features let you filter out inappropriate or harmful websites, giving parents more peace of mind about what their kids can access. Plus, its malware and phishing protection adds an extra layer of defense against online threats. Whether you're working, streaming, or managing your kids' screen time, AdGuard helps the whole family stay safer online without recurring costs. Secure your devices and your privacy for life — Use code FAMPLAN to get AdGuard Family Plan for just $15.97 until July 20. StackSocial prices subject to change. Opens in a new window Credit: AdGuard AdGuard Family Plan: Lifetime Subscription $15.97 $169.99 Save $154.02 Get Deal
Yahoo
2 days ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@